X

Trial Profile

BRCAAway: A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 01 Mar 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abiraterone acetate (Primary) ; Olaparib (Primary) ; Prednisone (Primary)
Indications Adenocarcinoma; Prostate cancer
Focus Therapeutic Use
Acronyms BRCAAWAY

Most Recent Events

27 Jan 2024 Results (n=61) assessing safety and efficacy of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer presented at the 2024 Genitourinary Cancers Symposium
28 Aug 2023 Planned End Date changed from 1 Jan 2022 to 16 Jan 2027.
28 Aug 2023 Planned primary completion date changed from 1 Dec 2021 to 16 Dec 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com